Todd DOLLINGER

Todd DOLLINGER

Founder and Chair Emeritus,
The Trendlines Group

Todd has more than four decades of wide-ranging business development, investment, and entrepreneurial experience, including being involved in the founding of more than 100 companies.  He founded Israel- and Singapore-based The Trendlines Group with Steve Rhodes where they served jointly as chairs and CEOs of Trendlines for some 18 years.  

Todd and his family moved to Israel in 1990 where he joined Israeli medical device start-up SRD Medical, later becoming SRD’s CEO.  Todd and Steve met at SRD, raised funds internationally for the company and brought the company’s product to market; SRD was acquired by Draeger Medical.  In 1993, Todd and Steve founded international business development firm Trendlines International, later merging the activities of Trendlines International Ltd. into The Trendlines Group.

In the course of their more than 30-year business partnership, Todd and Steve oversaw Trendlines’ IPO on the Singapore Stock Exchange in 2015 and have raised funds around the world for Trendlines, its venture funds, and portfolio companies. They have exited portfolio companies to multinational corporations, taken portfolio companies public, and have expanded the Group’s activities internationally, including establishing offices in Singapore, Shanghai, and Changzhou.

Todd chairs Trendlines’ investment committees in Israel and Singapore and serves as a director and chairs some of Trendlines’ portfolio companies; additionally, he consults to the non-profit Davos-based AO Foundation’s Technology Board which, inter alia, is responsible for allocating Development Incubator funds. 

Industry Advisory Panel

Subscribe To Our Newsletter

Join our mailing list to get updated with our latest news and events!

Contact Information
  • Lee Kong Chian School of
    Medicine,
    Clinical Sciences Building
    11 Mandalay Road #16-01
    Singapore 308232

  • +65 6904 1401
Members Login

co11ab Novena (co11ab) is a Bio MedTech incubator – forged through a tripartite alliance between Nanyang Technological University, Singapore (NTU Singapore), Agency for Science, Technology, and Research (A*STAR), and National Healthcare Group (NHG) – which aims to nurture and support the translational development of biomedical technologies. Our key focus areas are biotech, medtech and digital health.